
Accunea is a medical device company focused on organ transplantation, specifically kidney transplants. They are developing a technology that monitors organ condition in real-time using multiple biomarkers. This aims to reduce organ discard rates and improve patient recovery by providing clinicians with crucial data at the point-of-care. Their system offers insights into pre-transplant viability, kidney function (creatinine levels, GFR), and metabolic state. Accunea also utilizes an AI system for trend analysis and population comparisons to provide early warnings. The technology is designed for ease of use with a daily cartridge system and integrates with hospital EPR systems. The company collaborates with leading UK academics and transplant centers.

Accunea is a medical device company focused on organ transplantation, specifically kidney transplants. They are developing a technology that monitors organ condition in real-time using multiple biomarkers. This aims to reduce organ discard rates and improve patient recovery by providing clinicians with crucial data at the point-of-care. Their system offers insights into pre-transplant viability, kidney function (creatinine levels, GFR), and metabolic state. Accunea also utilizes an AI system for trend analysis and population comparisons to provide early warnings. The technology is designed for ease of use with a daily cartridge system and integrates with hospital EPR systems. The company collaborates with leading UK academics and transplant centers.
Focus: Point-of-care organ condition monitoring for kidney transplants
Stage: Early-stage medtech (pre-seed/seed activity reported)
Tech: Continuous biomarker monitoring (including continuous creatinine) and AI-enabled analytics
HQ: London, United Kingdom
Organ transplantation (kidney) — assessing organ viability and post-transplant function
2017
Biotechnology
Public profiles report a Seed round in March 2022; amount obfuscated in some sources.
“Newchip Accelerator, EIT Health, Innvotec, Panacea Stars”